Next Article in Journal
Effect of Aprotinin and Avifavir® Combination Therapy for Moderate COVID-19 Patients
Next Article in Special Issue
Comparative Study of Optical Markers to Assess Bait System Efficiency Concerning Vaccine Release in the Oral Cavity of Dogs
Previous Article in Journal
From Recoding to Peptides for MHC Class I Immune Display: Enriching Viral Expression, Virus Vulnerability and Virus Evasion
Previous Article in Special Issue
Oral Rabies Vaccination of Small Indian Mongooses (Urva auropunctata) with ONRAB via Ultralite Baits
Review

The Route of Administration of Rabies Vaccines: Comparing the Data

Department of Diagnostic Medicine/Pathobiology, College of Veterinary Medicine, Kansas State University, Manhattan, KS 66506, USA
*
Author to whom correspondence should be addressed.
Academic Editors: Ryan M. Wallace, Charles E. Rupprecht and Amy T. Gilbert
Viruses 2021, 13(7), 1252; https://doi.org/10.3390/v13071252
Received: 1 June 2021 / Revised: 24 June 2021 / Accepted: 25 June 2021 / Published: 27 June 2021
Cell culture rabies vaccines were initially licensed in the 1980s and are essential in the prevention of human rabies. The first post-exposure prophylaxis (PEP) vaccination regimen recommended by the World Health Organization (WHO) was administered intramuscularly over a lengthy three-month period. In efforts to reduce the cost of PEP without impinging on safety, additional research on two strategies was encouraged by the WHO including the development of less expensive production methods for CCVs and the administration of reduced volumes of CCVs via the intradermal (ID) route. Numerous clinical trials have provided sufficient data to support a reduction in the number of doses, a shorter timeline required for PEP, and the approval of the intradermal route of administration for PEP and pre-exposure prophylaxis (PreP). However, the plethora of data that have been published since the development of CCVs can be overwhelming for public health officials wishing to review and make a decision as to the most appropriate PEP and PreP regimen for their region. In this review, we examine three critical benchmarks that can serve as guidance for health officials when reviewing data to implement new PEP and PreP regimens for their region including: evidence of immunogenicity after vaccination; proof of efficacy against development of disease; and confirmation that the regimen being considered elicits a rapid anamnestic response after booster vaccination. View Full-Text
Keywords: rabies; post-exposure prophylaxis; PEP; pre-exposure vaccination; PreP; immunogenicity; efficacy; anamnestic response rabies; post-exposure prophylaxis; PEP; pre-exposure vaccination; PreP; immunogenicity; efficacy; anamnestic response
MDPI and ACS Style

Briggs, D.J.; Moore, S.M. The Route of Administration of Rabies Vaccines: Comparing the Data. Viruses 2021, 13, 1252. https://doi.org/10.3390/v13071252

AMA Style

Briggs DJ, Moore SM. The Route of Administration of Rabies Vaccines: Comparing the Data. Viruses. 2021; 13(7):1252. https://doi.org/10.3390/v13071252

Chicago/Turabian Style

Briggs, Deborah J., and Susan M. Moore. 2021. "The Route of Administration of Rabies Vaccines: Comparing the Data" Viruses 13, no. 7: 1252. https://doi.org/10.3390/v13071252

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop